

About Us



a subsidiary of SK biopharmaceuticals

We are part of SK Biopharmaceuticals, a growing biotech company focused on discovering and developing transformative therapies.

Our proprietary MOlecular Proximity Enabled Detection (MOPED™) molecular glue platform complements SK Life Science Labs' core targeted protein degradation (TPD) platform.

By leveraging our cutting-edge platforms and harnessing our deep drug-hunting expertise, we are determined to build a future where we'll change the outcome of currently life-altering diseases.

Our Pipeline

SK Life Science Labs' pipeline and platforms are well-positioned for partnering opportunities.


| Program | Disease Area | Discovery | Preclinical |
|---------------------------|----------------------|-----------|-------------|
| IKZF2 | Solid Tumors | PVTX-405 | |
| ER | HR+ Breast Cancer | PVTX-321 | |
| p300 | Oncology | | |
| STAT3 | Immunology, Oncology | | |
| SMARCA2 | Oncology | | |
| Heterobifunctional Target | Oncology | | |
| Molecular Glue Target | Oncology | | |

SK Life Science Labs

Proprietary drug discovery and preclinical development engine


MOPED™ Glue Platform

Induced proximity platform to find molecular glues that degrade difficult targets or perturb function



Core TPD Capabilities

Fully integrated cross-functional expertise from target identification through preclinical development



MOPED™ Leverages Induced Proximity To Discover Glues

Emerald

A highly sensitive biochemical workflow to discover glues against defined POIs

Sapphire

A cellular context-based workflow to discover glues against defined POIs

Molecular
Glue
Discovery

INCREASE ACCESS TO TARGETS

Targeting structured and unstructured regions

INCREASE NUMBER OF LEADS

Multiplexing compounds, targets, and/or E3s

EXPAND E3 OPPORTUNITIES

Known E3s, target matched E3s, and/or E3 agnostic

BROADEN BIOLOGICAL IMPACT

Exploring potential biological functions beyond TPD

Our Differentiated Approach Breaks Through Limits Of TPD

MOPED™ enables SK Life Science Labs to discover novel molecular glues utilizing an expanded set of E3s

Majority of TPD Companies

Most TPD companies primarily use CRBN and VHL, limiting target access



SK Life Science Labs leverages a wider range of E3s to expand target access



Contact Us

For more information, visit us at: www.skslabs.com

Strategic Alliance & Partnership Opportunities
Partnerships@SKLSLabs.com

Media Inquiries & PR
Media@SKLSLabs.com

General Business
Info@SKLSLabs.com